Thymosin Alpha-1 beat interferon in hepatitis B; sepsis data are mixed

What is Thymosin Alpha-1?

Thymosin Alpha-1 (thymalfasin, sold internationally as Zadaxin) is a synthetic 28-amino-acid, N-acetylated peptide identical to a fragment cleaved from prothymosin alpha, a protein the thymus and other tissues produce naturally. Thymosin Alpha-1 is approved in a number of countries as an adjunct for chronic hepatitis B and C. It is not FDA-approved in the United States.

Both facts are true at once, and neither answers the question that matters: how good the evidence is, and for what. Thymosin Alpha-1 has over 30 completed RCTs and more than 11,000 subjects behind it, and the quality of that evidence varies enormously by indication. Two other thymus-linked peptides, thymopentin and Thymogen, have their own evidence reviews.

How does Thymosin Alpha-1 act on the immune system?

Thymosin Alpha-1 acts as an immune modulator, not a booster: in trials it corrected specific, measurable dysfunctions rather than amplifying immunity in one direction. The forum framing of Thymosin Alpha-1 as an "immune booster" misdescribes the biology.

The proposed mechanism spans several nodes of immune regulation at once: T-cell maturation in the thymus, dendritic cell antigen presentation, Th1 response balance, and toll-like receptor (TLR) signaling. In the trial data, that combination shows up as a bidirectional effect, not a one-way amplification.

Each indication shows a different dysfunction being corrected:

• Sepsis. The relevant problem is often immune paralysis, a state where monocytes lose their capacity to present antigen. The 2013 ETASS trial measured this directly through monocyte HLA-DR expression and found it significantly improved by day 3 and day 7 in the treatment group ^[2].
• Severe COVID-19. The relevant problem was T-cell exhaustion, marked by elevated PD-1 and Tim-3 expression on CD8+ cells. The cohort study found Thymosin Alpha-1 associated with restored CD4+ and CD8+ counts and reduced exhaustion markers ^[3].
• Chronic hepatitis B. The antiviral effect was gradual and sustained rather than immediate, which the meta-analysis authors interpreted as consistent with immune modulation rather than a direct antiviral mechanism ^[1].

Does Thymosin Alpha-1 work for chronic hepatitis B?

Thymosin Alpha-1 outperformed interferon-alpha on virologic response at 6 months post-treatment in a 2008 meta-analysis of 4 hepatitis B RCTs ^[1].

The meta-analysis pooled 4 RCTs (n=199) and found an odds ratio of 3.71 (95% CI 2.05 to 6.71) for a significantly better virologic response with Thymosin Alpha-1 ^[1]. Chronic hepatitis B is the strongest ground the molecule stands on: real, randomized-trial-level support, in the specific context of chronic viral hepatitis.

Does Thymosin Alpha-1 reduce sepsis deaths?

Thymosin Alpha-1 did not reduce 28-day sepsis mortality in TESTS, the largest and most rigorous trial, after the smaller ETASS trial had reported a benefit ^[2]⁠^[4].

The 2013 ETASS trial (6 centers, n=361, single-blind) found 28-day mortality of 26.0% in the treatment group versus 35.0% in controls, a relative risk reduction that reached statistical significance (log-rank p=0.049) ^[2]. That result circulated widely and, for over a decade, was the largest randomized trial cited in support of the "Ta1 works for sepsis" claim. ETASS was also single-blind and modest in size.

The 2025 TESTS trial was built to settle the question: 22 centers, n=1106, double-blind, placebo-controlled, Phase 3. It found no significant difference in 28-day mortality (23.4% treatment vs 24.1% placebo, HR 0.97, 95% CI 0.76 to 1.24) ^[4]. That is a null result in the largest, most rigorous Thymosin Alpha-1 trial run in sepsis.

Exploratory subgroup analyses in TESTS suggested a possible benefit in patients aged 60 and older and in those with diabetes. Exploratory subgroups are hypothesis-generating, not confirmatory: they show where to look next, not what to conclude now. In an unselected sepsis population, Thymosin Alpha-1 did not help in the largest trial, and whether it helps an older or metabolically compromised subgroup is an open question the next trial would need to answer directly.

Does Thymosin Alpha-1 help severe COVID-19?

Thymosin Alpha-1 was linked to lower mortality in one cohort study of 76 severe COVID-19 patients treated in Wuhan ^[3], a signal that sits well below RCT-grade confidence.

Mortality was 11.1% in the treated group versus 30.0% in untreated controls (p=0.044), with evidence of T-cell exhaustion reversal ^[3]. Cohort studies carry real confounding risk: sicker or healthier patients can be selected into each arm for reasons beyond the drug itself.

The finding is a real, published signal worth taking seriously. No randomized COVID-19 trial is among the cited studies.

Does Thymosin Alpha-1 boost immunity in healthy people?

No cited trial shows that Thymosin Alpha-1 boosts immunity in healthy people. Every cited trial enrolled people with a defined, measurable immune abnormality: chronic viral infection, sepsis-driven immunoparalysis, or severe viral T-cell exhaustion.

A healthy immune system has no monocyte HLA-DR suppression or T-cell exhaustion to correct. None of the cited trials shows what, if anything, Thymosin Alpha-1 does to a system that is not dysregulated in the first place.

Extending those findings to a healthy 35-year-old taking the peptide prophylactically is not supported by the evidence. It is an inference the forums have made that the trial data do not make for them.

Where does the 1.6mg twice-weekly Thymosin Alpha-1 protocol come from?

The popular forum protocol of 1.6mg subcutaneously, twice weekly, matches the internationally approved hepatitis regimen and almost certainly originated there.

That dose and schedule were developed and tested for chronic viral hepatitis in that specific patient population. Nothing in the cited literature validates the same dose, frequency, or the "cycling" pattern common in peptide-forum protocols for general immune support in healthy users. Using the hepatitis regimen as a dosing anchor for a different purpose is extrapolation, not an established protocol.

A separate review covers the evidence behind peptide cycling schedules.

Is Thymosin Alpha-1 safe?

Thymosin Alpha-1 has been well tolerated across its trial base, and the TESTS trial confirmed a good safety profile even where efficacy was null ^[4].

Injection-site reactions (redness, mild pain, swelling) are the most consistently reported effect. Transient fatigue or a flu-like feeling after dosing occurs uncommonly, and rare rash or local irritation has been reported.

Two caution flags apply. Over-activating the immune response in people with autoimmune conditions is a theoretical concern, a caution rather than a documented frequent adverse event in the cited trials. Immunogenicity, the possibility of anti-drug antibody formation, is the second; FDA reviewers have cited it as part of the rationale around compounding-related risk.

What do Thymosin Alpha-1 trials still need to answer?

Thymosin Alpha-1's open questions concern who benefits beyond the patient groups already tested.

• Sepsis subgroups. Whether the age-60-plus and diabetes subgroup signals from TESTS represent a real, replicable effect or statistical noise from exploratory analysis remains unanswered ^[4].
• COVID-19. No cited study tests whether the cohort finding would hold up in a randomized, placebo-controlled trial ^[3].
• Healthy immune systems. The largest gap: no cited trial data show what Thymosin Alpha-1 does, if anything, to a healthy, non-dysregulated immune system over weeks or months of use.

That gap is not a dismissal of the molecule. It marks where the evidence stops.